Clinical Trials
3 trialsNCT00461591 2021-03-30
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT00598806 2017-11-13
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT00141531 2012-06-14
Phase II Trial of EOquin in High-risk Superficial Bladder Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed